Press Releases< /span>
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Oct 21, 2015
Cipher Pharmaceutiquired to build its commercial infrastructure in Canada. ____________________ 1 Source: IMS Health. Market share calculated based on total isotretinoin prescriptions. Product...
-
Oct 5, 2015
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that the Company, along with its partners, Ranbaxy Pharmaceuticals, Inc. ("Ranbaxy"), a Sun Pharma...
-
Aug 14, 2015
– Quarter Highlighted by Continued Solid Performance from Isotretinoin Products and Acquisition and Integration of Innocutis – MISSISSAUGA, ON, Aug. 14, 2015 /CNW/ - Cipher Pharmaceuticals...
-
Aug 4, 2015
- Acceptance marks first regulatory filing with FDA since Absorica® in 2011 - MISSISSAUGA, ON, Aug. 4, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company")...
-
Jul 31, 2015
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q2 2015 financial results on Friday, August 14, 2015. Q2 2015 CONFERENCE CALL WHEN:...
-
Jul 30, 2015
- Company expects to submit Ozenoxacin for regulatory approval in Canada in the first quarter of 2016 - MISSISSAUGA, ON, July 30, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH)...
-
Jun 19, 2015
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the 2015 JMP Securities Life Sciences...
-
Jun 4, 2015
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the BIO International Convention in...
-
Jun 2, 2015
- Company Adds Regulatory and Alliance Management Expertise to Support Expanded Product Portfolio - MISSISSAUGA, ON, June 2, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH)...
-
May 28, 2015
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the Jefferies 2015 Global Healthcare Conference in
-
May 14, 2015
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual and Special...
-
May 13, 2015
– Company Achieves Significant Progress Across All Three Components of Growth Strategy – MISSISSAUGA, ON, May 13, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or...
-
May 6, 2015
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has strengthened its Canadian dermatology portfolio by acquiring the Canadian rights to Vaniqa®...
-
Apr 29, 2015
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q1 2015 financial results and hold its Annual and Special Meeting of Shareholders on...
-
Apr 24, 2015
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that the Court has issued an opinion in the claim construction hearing (commonly referred to as a...
-
Apr 22, 2015
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the Bloom Burton & Co. Healthcare Investor...
-
Apr 13, 2015
Accelerates development of a leading North American dermatology company Adds U.S. commercial infrastructure for our acquisition/in-licensing activities Raises US$100 million Senior Notes to...
-
Mar 31, 2015
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will participate at the Laurentian Bank Securities 2nd Annual...
-
Mar 23, 2015
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by...
-
Feb 26, 2015
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the Cowen and Company 35th Annual Health Care...
-
Feb 26, 2015
– Strengthens dermatology product pipeline with rights to three products – MISSISSAUGA, ON, Feb. 26, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company")...
-
Feb 25, 2015
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three and 12 months ended December 31, 2014. Financial...
-
Feb 12, 2015
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that the Beteflam Patch (previously called the Betesil® Patch) has been accepted for review by...
-
Feb 9, 2015
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the 17th Annual BIO CEO & Investor Conference...
-
Feb 3, 2015
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q4 and year-end 2014 financial results on Wednesday, February 25, 2015. Q4 AND YEAR-END...
-
Jan 19, 2015
Company also announces promotions of Peter Weiler and Linda Angaritis MISSISSAUGA, ON, Jan. 19, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today...
-
Jan 9, 2015
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has acquired the assets of Melanovus Oncology Inc. ("Melanovus"), a Hershey (Pennsylvania)-based...
-
Jan 7, 2015
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that it has licensed the Canadian rights to Ozenoxacin, a topical treatment for adult and paediatric...
-
Dec 18, 2014
Cipher Pharmaceuticals Inc. (the "Company") (TSX: CPH; NASDAQ: CPHR) ("Cipher" or "the Company") announced today that its Board of Directors has approved a By-Law (the "Advance Notice By-Law")...
-
Nov 25, 2014
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the 26th Annual Piper Jaffray Healthcare...
-
Nov 20, 2014
Cipher Pharmaceuticals Inc. ("Cipher" or the "Company") (TSX:DND, NASDAQ:CPHR) today announced that its common shares have been approved for listing and trading on the NASDAQ Global Market (the...
-
Oct 29, 2014
- Company also announces application to list on NASDAQ - Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Oct. 29, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced its...
-
Oct 20, 2014
Cipher Pharmaceuticals Inc. (TSX: DND) (OTC: CPHMF), today announced it will host a conference call for its Q3 2014 financial results on Wednesday, October 29, 2014. Q3 2014 CONFERENCE CALL WHEN:...
-
Sep 3, 2014
Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced Shawn Patrick O'Brien, President and Chief Executive Officer, is presenting at the Rodman & Renshaw 16th Annual...
-
Jul 30, 2014
Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three and six months ended June 30, 2014. Q2 2014 Highlights Total revenue of $8.7 million, an...
-
Jul 24, 2014
Cipher Pharmaceuticals Inc. (TSX: DND) today announced it has entered into a definitive distribution and supply agreement with Ranbaxy Laboratories Ltd. ("Ranbaxy") under which Cipher has granted...
-
Jul 16, 2014
Cipher Pharmaceuticals Inc. (TSX: DND) (OTC: CPHMF), today announced it will host a conference call for its Q2 2014 financial results on Wednesday, July 30, 2014. Q2 2014 CONFERENCE CALL WHEN:...
-
Jun 26, 2014
Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien has been appointed Chief Executive Officer of Cipher, effective June 30. Mr. O'Brien...
-
Jun 18, 2014Cipher Pharmaceuticals completes distribution and supply agreement for isotretinoin product in Chile
Cipher Pharmaceuticals Inc. (TSX: DND) today announced it has entered into a definitive distribution and supply agreement with Laboratorios Andrómaco S.A. ("Andrómaco") under which Cipher has...
-
Jun 5, 2014Cipher Pharmaceuticals Inc. to present at the 2014 Bloom Burton & Co. Healthcare Investor Conference
Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that Norm Evans, Chief Financial Officer, is presenting at the 2014 Bloom Burton & Co. Healthcare Investor...
-
May 5, 2014
Cipher Pharmaceuticals Inc. (TSX: DND) ("the Company"), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual General Meeting of Shareholders held...
-
May 2, 2014
Company achieves ninth consecutive quarter of profitability Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, May 2, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced its...
-
Apr 21, 2014
Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced it will host a conference call for its Q1 2014 financial results and hold its Annual General Meeting of...
-
Mar 25, 2014
Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that Thomas G. Wellner has been appointed to the Board of Directors of the Company. Most recently, Mr. Wellner...
-
Mar 14, 2014
Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that Larry Andrews will be stepping down from his position as President and Chief Executive Officer. To ensure a...
-
Feb 26, 2014
Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three and twelve months ended December 31, 2013. Fiscal 2013 Highlights Total revenue of $27.0...
-
Feb 12, 2014
Cipher Pharmaceuticals Inc. (TSX: DND) (OTC: CPHMF), today announced it will host a conference call for its Q4 and Year-End 2013 financial results on Wednesday, February 26, 2014. Q4 and Year-End...
-
Feb 5, 2014
Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that Gerald (Gerry) McDole has been appointed as Chair of the Board of Directors of the Company effective...
-
Jan 21, 2014
Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that its marketing partner for Absoricaä has reached a cumulative sales milestone in accordance with the...
-
Dec 30, 2013
Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that William (Bill) Garriock has resigned from his position of Chair of Cipher, effective December 31, 2013, as...